PCM
RVNC

Prelude Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Prelude Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-202,180
Closed -$615K – 1616
2024
Q4 		$615K Sell
202,180
-1,020
-0.5% -$4.44K 0.04% 513
2024
Q3 		$1.05M Buy
+203,200
New +$1.01M 0.06% 373
2019
Q3 		– Sell
-1,880
Closed -$24K – 2139
2019
Q2 		$24K Buy
+1,880
New +$23.7K ﹤0.01% 1264
2018
Q4 		– Sell
-200
Closed -$5K – 2235
2018
Q3 		$5K Buy
+200
New +$5.44K ﹤0.01% 1631
2018
Q2 		– Sell
-12,970
Closed -$399K – 1999
2018
Q1 		$399K Sell
12,970
-4,012
-24% -$129K 0.03% 499
2017
Q4 		$607K Buy
16,982
+6,749
+66% +$194K 0.05% 367
2017
Q3 		$282K Sell
10,233
-5,892
-37% -$143K 0.03% 536
2017
Q2 		$426K Buy
16,125
+12,549
+351% +$280K 0.04% 361
2017
Q1 		$74K Buy
+3,576
New +$73.5K 0.01% 881
2016
Q1 		– Sell
-1,300
Closed -$44K – 1571
2015
Q4 		$44K Buy
+1,300
New +$45.1K 0.01% 1072

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prelude Capital Management's RVNC Position: Q1 2025 in Review

Prelude Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 202,180 shares — an estimated $615K sold.

Prelude Capital Management first reported a position in RVNC in Q4 2015 and held it in 10 quarters. The position peaked at $1.05M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Prelude Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Prelude Capital Management sold 202,180 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $615K.
  • Prelude Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 10 quarters.
  • Prelude Capital Management's Revance Therapeutics, Inc. position peaked at $1.05M in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.